Eterna Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 5.42 million compared to USD 9.38 million a year ago. Basic loss per share from continuing operations was USD 1.06 compared to USD 3.5 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.966 USD | +1.19% | -0.68% | +9.55% |
May. 14 | Eterna Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 08 | Eterna Therapeutics Inc. Appoints Mahendra Rao to Its Scientific Advisory Board | CI |
1st Jan change | Capi. | |
---|---|---|
+9.55% | 10.51M | |
+35.09% | 51.07B | |
-7.68% | 38.78B | |
+35.88% | 38.61B | |
-10.62% | 27.32B | |
+11.67% | 26.35B | |
-17.91% | 19.46B | |
+40.67% | 13.58B | |
+29.64% | 12.46B | |
-3.06% | 11.75B |
- Stock Market
- Equities
- ERNA Stock
- News Eterna Therapeutics Inc.
- Eterna Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023